文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

全脑放疗联合局部加量或为小细胞肺癌脑转移的适宜策略:多中心研究

Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study.
PubMed 文献 · Radiat Oncol · 2020-03-25

该多中心回顾性研究纳入2012年1月至2018年12月接受脑放疗的263例小细胞肺癌脑转移患者,比较全脑放疗联合局部加量(WBRT+boost)、单纯全脑放疗(WBRT)与立体定向放射外科(SRS)的疗效。结果显示WBRT+boost的总生存优于WBRT,在匹配患者中亦优于SRS,颅内无进展生存同样占优,提示WBRT+boost可能是优选策略。

要点

  • 全部患者中WBRT+boost总生存17.9个月,优于WBRT的8.7个月(P<0.001)。
  • 140例匹配患者中WBRT+boost总生存17.9个月,优于WBRT的11.7个月(P=0.045)。
  • WBRT+boost的颅内无进展生存优于WBRT(10.8 vs 6.5个月,P=0.005)与SRS(10.8 vs 7.5个月,P=0.032)。

核心结论

  • 对SCLC脑转移患者,全脑放疗联合局部加量可能因更好的生存时间而成为优选策略。

研究设计与样本

  • 多中心回顾性研究,回顾性筛选2012年1月至2018年12月接受WBRT或SRS的小细胞肺癌脑转移患者。
  • 共纳入263例符合条件的患者,其中女性73例、男性190例,按所接受的脑放疗分为WBRT+boost、WBRT和SRS三组。

主要发现

  • 全部患者中WBRT+boost组总生存长于WBRT组(17.9 vs 8.7个月;P<0.001)。
  • 140例匹配患者中WBRT+boost组总生存长于WBRT组(17.9 vs 11.7个月;P=0.045)。
  • 全部患者中WBRT+boost与SRS组总生存无显著差异(17.9 vs 14.5个月;P=0.432)。
  • 74例匹配患者中WBRT+boost组总生存长于SRS组(21.8 vs 12.9个月;P=0.040)。
  • 颅内无进展生存方面,WBRT+boost组优于WBRT组(10.8 vs 6.5个月;P=0.005)和SRS组(10.8 vs 7.5个月;P=0.032)。

临床怎么用

  • 对SCLC多发脑转移患者,可考虑在全脑放疗基础上联合局部加量以改善生存与颅内控制。

局限性

  • 为回顾性多中心研究,原文摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment for brain metastases in small cell lung cancer (SCLC) is still controversial. The purpose of this study was to compare different brain radiotherapy treatments on SCLC patients with brain metastases. METHODS: In this multi-center retrospective study, SCLC patients who had undergone whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) for brain metastases from January 2012 to December 2018 were retrospectively screened. RESULTS: A total of 263 eligible SCLC patients were included in this study, among whom, 73 were women and 190 were men. According to accepted brain radiotherapy, the remaining patients were divided into WBRT plus focal radiation boost (WBRT+boost), WBRT, and SRS groups. In pairwise comparisons of the overall survival (OS), WBRT+boost group led to longer survival than did WBRT both in all patients (17.9 vs 8.7 months; P < 0.001) and 140 matched patients (17.9 vs 11.7 months; P = 0.045). There were no significant differences in OS between WBRT+boost and SRS groups in all patients (17.9 vs 14.5 months; P = 0.432). Among 74 matched patients between WBRT+boost and SRS groups, however, patients who received WBRT+boost led to a longer survival than did SRS alone (21.8 vs 12.9 months; P = 0.040). In pairwise comparison of the intracranial progression-free survival time (iPFS), WBRT+boost group also showed survival advantages over WBRT (10.8 vs 6.5 months; P = 0.005) and SRS groups (10.8 vs 7.5 months; P = 0.032). CONCLUSION: Due to the SCLC-derived multiple brain metastases and better survival time, focal radiation boost combined with adjuvant WBRT may be a preferred strategy for SCLC patients with brain metastases.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ni M, Jiang A, Liu W, et al. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study. Radiat Oncol. 2020. PMID: 32213185. doi:10.1186/s13014-020-01509-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。